Therapeutic subgroup
H01 – HYPOPHYSEN- UND HYPOTHALAMUSHORMONE UND ANALOGA
- Anatomical main group H: SYSTEMISCHE HORMONPRÄPARATE, EXKL. SEXUALHORMONE UND INSULINE
9Decisions
11Patient groups
Added benefit by patient group
- Considerable1
- Minor2
- Non-quantifiable4
- Not proven4
Subgroups
- H01A HYPOPHYSENVORDERLAPPENHORMONE UND ANALOGA 3 decisions
- H01C HYPOTHALAMUSHORMONE 6 decisions
Decisions, newest first
- 2025-06-05YseltyLinzagolixNot proven
- 2025-03-06YseltyLinzagolixNot proven
- 2024-05-16RyeqoRelugolix/Estradiol/NorethisteronNot proven
- 2024-05-02SogroyaSomapacitanNon-quantifiable: 2 of 2 patient groups
- 2024-03-07SkytrofaLonapegsomatropinNon-quantifiable
- 2022-09-15NgenlaSomatrogonNon-quantifiable
- 2022-02-17RyeqoRelugolix/Estradiol/NorethisteronConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2015-06-18SigniforPasireotidMinor
- 2012-12-06SigniforPasireotidMinor
Data status: 2026-10-29